<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="editorial"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Antimicrob Agents</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Antimicrob. Agents</journal-id><journal-title-group><journal-title>International Journal of Antimicrobial Agents</journal-title></journal-title-group><issn pub-type="ppub">0924-8579</issn><issn pub-type="epub">1872-7913</issn><publisher><publisher-name>Published by Elsevier B.V.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7135139</article-id><article-id pub-id-type="publisher-id">S0924-8579(20)30082-0</article-id><article-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105932</article-id><article-id pub-id-type="publisher-id">105932</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Chloroquine and hydroxychloroquine as available weapons to fight COVID-19</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name><surname>Colson</surname><given-names>Philippe</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0002"><name><surname>Rolain</surname><given-names>Jean-Marc</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0003"><name><surname>Lagier</surname><given-names>Jean-Christophe</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0004"><name><surname>Brouqui</surname><given-names>Philippe</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0005"><name><surname>Raoult</surname><given-names>Didier</given-names></name><email>didier.raoult@gmail.com</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref><xref rid="cor0001" ref-type="corresp">&#x0204e;</xref></contrib><aff id="aff0001"><label>a</label>Aix-Marseille Universit&#x000e9;, Institut de Recherche pour le D&#x000e9;veloppement (IRD), Assistance Publique&#x02013;H&#x000f4;pitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 Marseille, France</aff><aff id="aff0002"><label>b</label>IHU M&#x000e9;diterran&#x000e9;e Infection, 19&#x02013;21 boulevard Jean Moulin, 13005 Marseille, France</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#x0204e;</label>Corresponding author. Present address: IHU M&#x000e9;diterran&#x000e9;e Infection, 19&#x02013;21 boulevard Jean Moulin, 13005 Marseille, France. Tel.: +33 4 13 732 401; fax: +33 4 13 732 402. <email>didier.raoult@gmail.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>4</day><month>3</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>4</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>4</day><month>3</month><year>2020</year></pub-date><volume>55</volume><issue>4</issue><fpage>105932</fpage><lpage>105932</lpage><history><date date-type="received"><day>26</day><month>2</month><year>2020</year></date><date date-type="accepted"><day>27</day><month>2</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Published by Elsevier B.V.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder/><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions></article-meta></front><body><p id="para0001">Repositioning of drugs for use as antiviral treatments is a critical need <xref rid="bib0001" ref-type="bibr">[1]</xref>. It is commonly very badly perceived by virologists, as we experienced when reporting the effectiveness of azithromycin for Zika virus <xref rid="bib0002" ref-type="bibr">[2]</xref>. A response has come from China to the respiratory disease caused by the new coronavirus (SARS-CoV-2) that emerged in December 2019 in this country. Indeed, following the very recent publication of results showing the in vitro activity of chloroquine against SARS-CoV-2 <xref rid="bib0003" ref-type="bibr">[3]</xref>, data have been reported on the efficacy of this drug in patients with SARS-CoV-2-related pneumonia (named COVID-19) at different levels of severity <xref rid="bib0004" ref-type="bibr">[4</xref>,<xref rid="bib0005" ref-type="bibr">5]</xref>. Thus, following the in vitro results, 20 clinical studies were launched in several Chinese hospitals. The first results obtained from more than 100 patients showed the superiority of chloroquine compared with treatment of the control group in terms of reduction of exacerbation of pneumonia, duration of symptoms and delay of viral clearance, all in the absence of severe side effects <xref rid="bib0004" ref-type="bibr">[4</xref>,<xref rid="bib0005" ref-type="bibr">5]</xref>. This has led in China to include chloroquine in the recommendations regarding the prevention and treatment of COVID-19 pneumonia <xref rid="bib0004" ref-type="bibr">[4</xref>,<xref rid="bib0006" ref-type="bibr">6]</xref>.</p><p id="para0002">There is a strong rationality for the use of chloroquine to treat infections with intracellular micro-organisms. Thus, malaria has been treated for several decades with this molecule <xref rid="bib0007" ref-type="bibr">[7]</xref>. In addition, our team has used hydroxychloroquine for the first time for intracellular bacterial infections since 30 years to treat the intracellular bacterium <italic>Coxiella burnetii</italic>, the agent of Q fever, for which we have shown in vitro and then in patients that this compound is the only one efficient for killing these intracellular pathogens <xref rid="bib0008" ref-type="bibr">[8</xref>,<xref rid="bib0009" ref-type="bibr">9]</xref>. Since then, we have also shown the activity of hydroxychloroquine on <italic>Tropheryma whipplei</italic>, the agent of Whipple's disease, which is another intracellular bacterium for which hydroxychloroquine has become a reference drug <xref rid="bib0010" ref-type="bibr">[10</xref>,<xref rid="bib0011" ref-type="bibr">11]</xref>. Altogether, one of us (DR) has treated ~4000 cases of <italic>C. burnetii</italic> or <italic>T. whipplei</italic> infections over 30 years (personal data).</p><p id="para0003">Regarding viruses, for reasons probably partly identical involving alkalinisation by chloroquine of the phagolysosome, several studies have shown the effectiveness of this molecule, including against coronaviruses among which is the severe acute respiratory syndrome (SARS)-associated coronavirus <xref rid="bib0001" ref-type="bibr">[1</xref>,<xref rid="bib0012" ref-type="bibr">12</xref>,<xref rid="bib0013" ref-type="bibr">13]</xref> (<xref rid="tbl0001" ref-type="table">Table 1</xref>
). We previously emphasised interest in chloroquine for the treatment of viral infections in this journal <xref rid="bib0001" ref-type="bibr">[1]</xref>, predicting its use in viral infections lacking drugs. Following the discovery in China of the in vitro activity of chloroquine against SARS-CoV-2, discovered during culture tests on Vero E6 cells with 50% and 90% effective concentrations (EC<sub>50</sub> and EC<sub>90</sub> values) of 1.13 &#x003bc;M and 6.90 &#x003bc;M, respectively (antiviral activity being observed when addition of this drug was carried out before or after viral infection of the cells) <xref rid="bib0003" ref-type="bibr">[3]</xref>, we awaited with great interest the clinical data <xref rid="bib0014" ref-type="bibr">[14]</xref>. The subsequent in vivo data were communicated following the first results of clinical trials by Chinese teams <xref rid="bib0004" ref-type="bibr">[4]</xref> and also aroused great enthusiasm among us. They showed that chloroquine could reduce the length of hospital stay and improve the evolution of COVID-19 pneumonia <xref rid="bib0004" ref-type="bibr">[4</xref>,<xref rid="bib0006" ref-type="bibr">6]</xref>, leading to recommend the administration of 500 mg of chloroquine twice a day in patients with mild, moderate and severe forms of COVID-19 pneumonia. At such a dosage, a therapeutic concentration of chloroquine might be reached. With our experience on 2000 dosages of hydroxychloroquine during the past 5 years in patients with long-term treatment (&#x0003e;1 year), we know that with a dosage of 600 mg/day we reach a concentration of 1 &#x003bc;g/mL <xref rid="bib0015" ref-type="bibr">[15]</xref>. The optimal dosage for SARS-CoV-2 is an issue that will need to be assessed in the coming days. For us, the activity of hydroxychloroquine on viruses is probably the same as that of chloroquine since the mechanism of action of these two molecules is identical, and we are used to prescribe for long periods hydroxychloroquine, which would be therefore our first choice in the treatment of SARS-CoV-2. For optimal treatment, it may be necessary to administer a loading dose followed by a maintenance dose.<table-wrap position="float" id="tbl0001"><label>Table 1</label><caption><p>Main results of studies on the activity of chloroquine or hydroxychloroquine on coronaviruses<xref rid="tb1fn1" ref-type="table-fn">a</xref></p></caption><alt-text id="alt0001">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reference</th><th valign="top">Compound(s)</th><th valign="top">Targeted virus</th><th valign="top">System used for antiviral activity screening</th><th valign="top">Antiviral effect</th></tr></thead><tbody><tr><td valign="top"><xref rid="bib0012" ref-type="bibr">[12]</xref></td><td valign="top">Chloroquine</td><td valign="top">SARS-CoV</td><td valign="top">Vero (African green monkey kidney) E6 cells</td><td valign="top">EC<sub>50</sub>&#x000a0;=&#x000a0;8.8 &#x000b1; 1.2 &#x003bc;M</td></tr><tr><td valign="top"><xref rid="bib0016" ref-type="bibr">[16]</xref></td><td valign="top">Chloroquine</td><td valign="top"/><td valign="top">Vero E6 cells</td><td valign="top">EC<sub>50</sub>&#x000a0;=&#x000a0;4.4 &#x000b1; 1.0 &#x003bc;M</td></tr><tr><td valign="top"><xref rid="bib0017" ref-type="bibr">[17]</xref></td><td valign="top">Chloroquine, chloroquine monophosphate, chloroquine diphosphate</td><td valign="top">SARS-CoV (four strains)</td><td valign="top">Vero 76 cells</td><td valign="top">Chloroquine: EC<sub>50</sub>&#x000a0;=&#x000a0;1&#x02013;4 &#x003bc;M<break/>Chloroquine monophosphate: EC<sub>50</sub>&#x000a0;=&#x000a0;4&#x02013;6 &#x003bc;M<break/>Chloroquine diphosphate: EC<sub>50</sub>&#x000a0;=&#x000a0;3&#x02013;4 &#x003bc;M</td></tr><tr><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">BALB/c mice</td><td valign="top">Intraperitoneal or intranasal chloroquine administration, beginning 4 h prior to virus exposure: 50 mg/kg but not 10 mg/kg or 1 mg/kg reduced for the intranasal route (but not the intraperitoneal route) viral lung titres from mean &#x000b1; S.D. of 5.4 &#x000b1; 0.5 to 4.4 &#x000b1; 1.2 in log<sub>10</sub> CCID<sub>50</sub>/g at Day 3 (considered as not significant)</td></tr><tr><td valign="top"><xref rid="bib0018" ref-type="bibr">[18]</xref></td><td valign="top">Chloroquine, hydroxychloroquine</td><td valign="top">SARS-CoV</td><td valign="top">Vero cells</td><td valign="top">Chloroquine: EC<sub>50</sub>&#x000a0;=&#x000a0;6.5 &#x000b1; 3.2 &#x003bc;M<break/>Hydroxychloroquine: EC<sub>50</sub>&#x000a0;=&#x000a0;34 &#x000b1; 5 &#x003bc;M</td></tr><tr><td valign="top"/><td valign="top"/><td valign="top">Feline coronavirus</td><td valign="top">Crandell&#x02013;Reese feline kidney (CRFK) cells</td><td valign="top">Chloroquine: EC<sub>50</sub> &#x0003e; 0.8 &#x003bc;M<break/>Hydroxychloroquine: EC<sub>50</sub>&#x000a0;=&#x000a0;28 &#x000b1; 27 &#x003bc;M</td></tr><tr><td valign="top"><xref rid="bib0019" ref-type="bibr">[19]</xref></td><td valign="top">Chloroquine</td><td valign="top">HCoV-229E</td><td valign="top">Human epithelial lung cells (L132)</td><td valign="top">Chloroquine at concentrations of 10 &#x003bc;M and 25 &#x003bc;M inhibited HCoV-229E release into the culture supernatant</td></tr><tr><td valign="top"><xref rid="bib0020" ref-type="bibr">[20]</xref></td><td valign="top">Chloroquine</td><td valign="top">HCoV-OC43</td><td valign="top">HRT-18 cells</td><td valign="top">EC<sub>50</sub>&#x000a0;=&#x000a0;0.306 &#x000b1; 0.0091 &#x003bc;M</td></tr><tr><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">Newborn C57BL/6 mice; chloroquine administration transplacentally and via maternal milk</td><td valign="top">100%, 93%, 33% and 0% survival rate of pups when mother mice were treated per day with 15, 5, 1 and 0 mg/kg body weight, respectively</td></tr><tr><td valign="top"><xref rid="bib0021" ref-type="bibr">[21]</xref></td><td valign="top">Chloroquine</td><td valign="top">Feline infectious peritonitis virus (FIPV)</td><td valign="top"><italic>Felis catus</italic> whole fetus-4 cells</td><td valign="top">FIPV replication was inhibited in a chloroquine concentration-dependent manner</td></tr><tr><td valign="top"><xref rid="bib0022" ref-type="bibr">[22]</xref></td><td valign="top">Chloroquine</td><td valign="top">SARS-CoV</td><td valign="top">Vero E6 cells</td><td valign="top">EC<sub>50</sub>&#x000a0;=&#x000a0;4.1 &#x000b1; 1.0 &#x003bc;M</td></tr><tr><td valign="top"/><td valign="top"/><td valign="top">MERS-CoV</td><td valign="top">Huh7 cells (human liver cell line)</td><td valign="top">EC<sub>50</sub>&#x000a0;=&#x000a0;3.0 &#x000b1; 1.1 &#x003bc;M</td></tr><tr><td valign="top"/><td valign="top"/><td valign="top">HCoV-229E-GFP (GFP-expressing recombinant HCoV-229E)</td><td valign="top">Huh7 cells (human liver cell line)</td><td valign="top">EC<sub>50</sub>&#x000a0;=&#x000a0;3.3 &#x000b1; 1.2 &#x003bc;M</td></tr><tr><td valign="top"><xref rid="bib0003" ref-type="bibr">[3]</xref></td><td valign="top">Chloroquine</td><td valign="top">SARS-CoV-2</td><td valign="top">Vero E6 cells</td><td valign="top">EC<sub>50</sub>&#x000a0;=&#x000a0;1.13 &#x003bc;M</td></tr></tbody></table><table-wrap-foot><fn><p>CCID<sub>50</sub>, 50% cell culture infectious dose; CoV, coronavirus; EC<sub>50</sub>, 50% effective concentration (mean &#x000b1; S.D.); GFP, green fluorescent protein; HCoV, human coronavirus; MERS, Middle East respiratory syndrome; SARS, severe acute respiratory syndrome; S.D., standard deviation.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb1fn1"><label>a</label><p id="notep0002">See also <xref rid="bib0001" ref-type="bibr">[1]</xref> (<xref rid="tbl0001" ref-type="table">Table 1</xref>) for additional references.</p></fn></table-wrap-foot></table-wrap></p></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name><surname>Rolain</surname><given-names>J.M.</given-names></name><name><surname>Colson</surname><given-names>P.</given-names></name><name><surname>Raoult</surname><given-names>D.</given-names></name></person-group><article-title>Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century</article-title><source>Int J Antimicrob Agents</source><volume>30</volume><year>2007</year><fpage>297</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2007.05.015</pub-id><pub-id pub-id-type="pmid">17629679</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name><surname>Bosseboeuf</surname><given-names>E.</given-names></name><name><surname>Aubry</surname><given-names>M.</given-names></name><name><surname>Nhan</surname><given-names>T.</given-names></name><name><surname>de Pina</surname><given-names>J.J.</given-names></name><name><surname>Rolain</surname><given-names>J.M.</given-names></name><name><surname>Raoult</surname><given-names>D.</given-names></name></person-group><article-title>Azithromycin inhibits the replication of Zika virus</article-title><source>J Antivir Antiretrovir</source><volume>10</volume><year>2018</year><fpage>6</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.4172/1948-5964.1000173</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title><source>Cell Res</source><year>2020 Feb 4</year><pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Tian</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies</article-title><source>Biosci Trends</source><year>2020 Feb 19</year><pub-id pub-id-type="doi">10.5582/bst.2020.01047</pub-id><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib0005"><label>5</label><mixed-citation publication-type="other" id="othref0001">Chinese Clinical Trial Registry. <ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/searchproj.aspx?title=%E6%B0%AF%E5%96%B9&#x00026;officialname=&#x00026;subjectid=&#x00026;secondaryid=&#x00026;applier=&#x00026;studyleader=&#x00026;ethicalcommitteesanction=&#x00026;sponsor=&#x00026;studyailment=&#x00026;studyailmentcode=&#x00026;studytype=0&#x00026;studystage=0&#x00026;studydesign=0&#x00026;minstudyexecutetime=&#x00026;maxstudyexecutetime=&#x00026;recruitmentstatus=0&#x00026;gender=0&#x00026;agreetosign=&#x00026;secsponsor=&#x00026;regno=&#x00026;regstatus=0&#x00026;country=&#x00026;province=&#x00026;city=&#x00026;institution=&#x00026;institutionlevel=&#x00026;measure=&#x00026;intercode=&#x00026;sourceofspends=&#x00026;createyear=0&#x00026;isuploadrf=&#x00026;whetherpublic=&#x00026;btngo=btn&#x00026;verifycode=&#x00026;page=1" id="interref0001">http://www.chictr.org.cn/searchproj.aspx?title=%E6%B0%AF%E5%96%B9&#x00026;officialname=&#x00026;subjectid=&#x00026;secondaryid=&#x00026;applier=&#x00026;studyleader=&#x00026;ethicalcommitteesanction=&#x00026;sponsor=&#x00026;studyailment=&#x00026;studyailmentcode=&#x00026;studytype=0&#x00026;studystage=0&#x00026;studydesign=0&#x00026;minstudyexecutetime=&#x00026;maxstudyexecutetime=&#x00026;recruitmentstatus=0&#x00026;gender=0&#x00026;agreetosign=&#x00026;secsponsor=&#x00026;regno=&#x00026;regstatus=0&#x00026;country=&#x00026;province=&#x00026;city=&#x00026;institution=&#x00026;institutionlevel=&#x00026;measure=&#x00026;intercode=&#x00026;sourceofspends=&#x00026;createyear=0&#x00026;isuploadrf=&#x00026;whetherpublic=&#x00026;btngo=btn&#x00026;verifycode=&#x00026;page=1</ext-link>.</mixed-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><collab>Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia</collab></person-group><article-title>Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia [in Chinese]</article-title><source>Zhonghua Jie He He Hu Xi Za Zhi</source><volume>43</volume><year>2020</year><fpage>E019</fpage><pub-id pub-id-type="doi">10.3760/cma.j.issn.1001-0939.2020.0019</pub-id><pub-id pub-id-type="pmid">32075365</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name><surname>Al-Bari</surname><given-names>M.A.</given-names></name></person-group><article-title>Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases</article-title><source>J Antimicrob Chemother</source><volume>70</volume><year>2015</year><fpage>1608</fpage><lpage>1621</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv018</pub-id><pub-id pub-id-type="pmid">25693996</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name><surname>Raoult</surname><given-names>D.</given-names></name><name><surname>Drancourt</surname><given-names>M.</given-names></name><name><surname>Vestris</surname><given-names>G.</given-names></name></person-group><article-title>Bactericidal effect of doxycycline associated with lysosomotropic agents on <italic>Coxiella burnetii</italic> in P388D1 cells</article-title><source>Antimicrob Agents Chemother</source><volume>34</volume><year>1990</year><fpage>1512</fpage><lpage>1514</lpage><pub-id pub-id-type="doi">10.1128/aac.34.8.1512</pub-id><pub-id pub-id-type="pmid">2221859</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name><surname>Raoult</surname><given-names>D.</given-names></name><name><surname>Houpikian</surname><given-names>P.</given-names></name><name><surname>Tissot Dupont</surname><given-names>H.</given-names></name><name><surname>Riss</surname><given-names>J.M.</given-names></name><name><surname>Arditi-Djiane</surname><given-names>J.</given-names></name><name><surname>Brouqui</surname><given-names>P.</given-names></name></person-group><article-title>Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine</article-title><source>Arch Intern Med</source><volume>159</volume><year>1999</year><fpage>167</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1001/archinte.159.2.167</pub-id><pub-id pub-id-type="pmid">9927100</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name><surname>Boulos</surname><given-names>A.</given-names></name><name><surname>Rolain</surname><given-names>J.M.</given-names></name><name><surname>Raoult</surname><given-names>D.</given-names></name></person-group><article-title>Antibiotic susceptibility of <italic>Tropheryma whipplei</italic> in MRC5 cells</article-title><source>Antimicrob Agents Chemother</source><volume>48</volume><year>2004</year><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1128/aac.48.3.747-752.2004</pub-id><pub-id pub-id-type="pmid">14982759</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Fenollar</surname><given-names>F.</given-names></name><name><surname>Pu&#x000e9;chal</surname><given-names>X.</given-names></name><name><surname>Raoult</surname><given-names>D.</given-names></name></person-group><article-title>Whipple's disease</article-title><source>N Engl J Med</source><volume>356</volume><year>2007</year><fpage>55</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1056/NEJMra062477</pub-id><pub-id pub-id-type="pmid">17202456</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name><surname>Keyaerts</surname><given-names>E.</given-names></name><name><surname>Vijgen</surname><given-names>L.</given-names></name><name><surname>Maes</surname><given-names>P.</given-names></name><name><surname>Neyts</surname><given-names>J.</given-names></name><name><surname>Van Ranst</surname><given-names>M.</given-names></name></person-group><article-title>In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine</article-title><source>Biochem Biophys Res Commun</source><volume>323</volume><year>2004</year><fpage>264</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2004.08.085</pub-id><pub-id pub-id-type="pmid">15351731</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name><surname>Savarino</surname><given-names>A.</given-names></name><name><surname>Di Trani</surname><given-names>L.</given-names></name><name><surname>Donatelli</surname><given-names>I.</given-names></name><name><surname>Cauda</surname><given-names>R.</given-names></name><name><surname>Cassone</surname><given-names>A.</given-names></name></person-group><article-title>New insights into the antiviral effects of chloroquine</article-title><source>Lancet Infect Dis</source><volume>6</volume><year>2006</year><fpage>67</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(06)70361-9</pub-id><pub-id pub-id-type="pmid">16439323</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name><surname>Colson</surname><given-names>P.</given-names></name><name><surname>Rolain</surname><given-names>J.M.</given-names></name><name><surname>Raoult</surname><given-names>D.</given-names></name></person-group><article-title>Chloroquine for the 2019 novel coronavirus SARS-CoV-2</article-title><source>Int J Antimicrob Agents</source><year>2020</year><object-id pub-id-type="publisher-id">105923</object-id><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105923</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name><surname>Lagier</surname><given-names>J.C.</given-names></name><name><surname>Fenollar</surname><given-names>F.</given-names></name><name><surname>Lepidi</surname><given-names>H.</given-names></name><name><surname>Giorgi</surname><given-names>R.</given-names></name><name><surname>Million</surname><given-names>M.</given-names></name><name><surname>Raoult</surname><given-names>D.</given-names></name></person-group><article-title>Treatment of classic Whipple's disease: from in vitro results to clinical outcome</article-title><source>J Antimicrob Chemother</source><volume>69</volume><year>2014</year><fpage>219</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1093/jac/dkt310</pub-id><pub-id pub-id-type="pmid">23946319</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>M.J.</given-names></name><name><surname>Bergeron</surname><given-names>E.</given-names></name><name><surname>Benjannet</surname><given-names>S.</given-names></name><name><surname>Erickson</surname><given-names>B.R.</given-names></name><name><surname>Rollin</surname><given-names>P.E.</given-names></name><name><surname>Ksiazek</surname><given-names>T.G.</given-names></name></person-group><article-title>Chloroquine is a potent inhibitor of SARS coronavirus infection and spread</article-title><source>Virol J</source><volume>2</volume><year>2005</year><fpage>69</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-2-69</pub-id><pub-id pub-id-type="pmid">16115318</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name><surname>Barnard</surname><given-names>D.L.</given-names></name><name><surname>Day</surname><given-names>C.W.</given-names></name><name><surname>Bailey</surname><given-names>K.</given-names></name><name><surname>Heiner</surname><given-names>M.</given-names></name><name><surname>Montgomery</surname><given-names>R.</given-names></name><name><surname>Lauridsen</surname><given-names>L.</given-names></name></person-group><article-title>Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice</article-title><source>Antivir Chem Chemother</source><volume>17</volume><year>2006</year><fpage>275</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1177/095632020601700505</pub-id><pub-id pub-id-type="pmid">17176632</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name><surname>Biot</surname><given-names>C.</given-names></name><name><surname>Daher</surname><given-names>W.</given-names></name><name><surname>Chavain</surname><given-names>N.</given-names></name><name><surname>Fandeur</surname><given-names>T.</given-names></name><name><surname>Khalife</surname><given-names>J.</given-names></name><name><surname>Dive</surname><given-names>D.</given-names></name></person-group><article-title>Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities</article-title><source>J Med Chem</source><volume>49</volume><year>2006</year><fpage>2845</fpage><lpage>2849</lpage><pub-id pub-id-type="doi">10.1021/jm0601856</pub-id><pub-id pub-id-type="pmid">16640347</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name><surname>Kono</surname><given-names>M.</given-names></name><name><surname>Tatsumi</surname><given-names>K.</given-names></name><name><surname>Imai</surname><given-names>A.M.</given-names></name><name><surname>Saito</surname><given-names>K.</given-names></name><name><surname>Kuriyama</surname><given-names>T.</given-names></name><name><surname>Shirasawa</surname><given-names>H.</given-names></name></person-group><article-title>Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK</article-title><source>Antiviral Res</source><volume>77</volume><year>2008</year><fpage>150</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2007.10.011</pub-id><pub-id pub-id-type="pmid">18055026</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name><surname>Keyaerts</surname><given-names>E.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Vijgen</surname><given-names>L.</given-names></name><name><surname>Rysman</surname><given-names>E.</given-names></name><name><surname>Verbeeck</surname><given-names>J.</given-names></name><name><surname>Van Ranst</surname><given-names>M.</given-names></name></person-group><article-title>Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice</article-title><source>Antimicrob Agents Chemother</source><volume>53</volume><year>2009</year><fpage>3416</fpage><lpage>3421</lpage><pub-id pub-id-type="doi">10.1128/AAC.01509-08</pub-id><pub-id pub-id-type="pmid">19506054</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Takano</surname><given-names>T.</given-names></name><name><surname>Katoh</surname><given-names>Y.</given-names></name><name><surname>Doki</surname><given-names>T.</given-names></name><name><surname>Hohdatsu</surname><given-names>T.</given-names></name></person-group><article-title>Effect of chloroquine on feline infectious peritonitis virus infection in vitro and in vivo</article-title><source>Antiviral Res</source><volume>99</volume><year>2013</year><fpage>100</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2013.04.016</pub-id><comment>7</comment><pub-id pub-id-type="pmid">23648708</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name><surname>de Wilde</surname><given-names>A.H.</given-names></name><name><surname>Jochmans</surname><given-names>D.</given-names></name><name><surname>Posthuma</surname><given-names>C.C.</given-names></name><name><surname>Zevenhoven-Dobbe</surname><given-names>J.C.</given-names></name><name><surname>van Nieuwkoop</surname><given-names>S.</given-names></name><name><surname>Bestebroer</surname><given-names>T.M.</given-names></name></person-group><article-title>Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture</article-title><source>Antimicrob Agents Chemother</source><volume>58</volume><year>2014</year><fpage>4875</fpage><lpage>4884</lpage><pub-id pub-id-type="doi">10.1128/AAC.03011-14</pub-id><pub-id pub-id-type="pmid">24841269</pub-id></element-citation></ref></ref-list><ack id="ack0001"><p>
<bold>Funding:</bold> This work was supported by the French Government under the &#x02018;Investments for the Future&#x02019; program managed by the National Agency for Research (ANR) [M&#x000e9;diterran&#x000e9;e Infection 10-IAHU-03]. The funding sources had no role in the preparation, review or approval of the manuscript.</p><p>
<bold>Competing interests:</bold> None declared.</p><p>
<bold>Ethical approval:</bold> Not required.</p></ack></back></article>